Amyotrophic lateral sclerosis

Insights on the Amyotrophic Lateral Sclerosis Treatment Global Market to 2029 - Rising Awareness and Incidence of ALS is Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 14, 2022
Health, Pharmaceutical, Hospital, Edaravone, Sun Pharma, Amyotrophic lateral sclerosis, Research report, Mitsubishi Tanabe Pharma, Prevalence, Medication, Treatment, ALS, Incidence, Pharmacy, Riluzole, Growth, Brainstorm, Region, Distribution, USD, Healthcare, Biogen

The global Amyotrophic Lateral Sclerosis (ALS) treatment market size is estimated to be USD 725.58 million in 2021 and is expected to witness a CAGR of 6.97% during the forecast period.

Key Points: 
  • The global Amyotrophic Lateral Sclerosis (ALS) treatment market size is estimated to be USD 725.58 million in 2021 and is expected to witness a CAGR of 6.97% during the forecast period.
  • Increasing geriatric population worldwide, rising awareness for ALS, and increase in incidence of ALS are some of the key factors expected to boost growth of the global market.
  • Conversely, the high cost related with ALS treatment is expected to hinder the growth during the forecast period.
  • Based on treatment, the amyotrophic lateral sclerosis treatment market is segmented into stem cell therapies, medications, and others.

Emerging Pipeline Therapeutics Across 6 Rare Neuromuscular Diseases: Strategic Partnering and New Product Development will Enable Better Biologics for Personalized and Targeted Treatment - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 13, 2022
Biotechnology, Pharmaceutical, Health, Myasthenia gravis, Sarepta, Therapy, Spinal muscular atrophy, CIDP, DN, US FDA, DMD, Disorder, Myopathy, SMA, Duchenne muscular dystrophy, NMD, Golodirsen, Motor neuron disease, Patient, Amyotrophic lateral sclerosis, US, Degenerative disease, Research, Neuromuscular Disorders, NMDS, ALS, Diabetic neuropathy, Eteplirsen, Muscle, Cramp, Quality of life, Muscle weakness, RNA, Patent, Pharmaceutical industry, Vaccine

Biologics presents a personalized and targeted method to treat NMDs and is a promising treatment class.

Key Points: 
  • Biologics presents a personalized and targeted method to treat NMDs and is a promising treatment class.
  • This research, "Emerging Therapeutics for Rare Neuromuscular Diseases: A Pipeline Analysis" explores emerging biologics across these six NMDs.
  • Key biologics emerging for these rare NMDs include stem cell therapies, other cell-based treatments, gene therapies, RNA therapeutics, immunotherapies, and other protein/peptide-based treatments.
  • Therefore, biologics are suitably poised to transform the rare NMD landscape with personalized and targeted treatment strategies and will provide life-saving treatment options for fatal neuromuscular conditions.

Verge Genomics Appoints Diego Cadavid, M.D., as Chief Medical Officer

Retrieved on: 
Tuesday, December 6, 2022
Biotechnology, Technology, Other Health, Health, Pharmaceutical, Health Technology, Other Science, Research, Artificial Intelligence, Science, Clinical Trials, Therapy, Publication, Probability, Armed Forces Institute of Pathology, Fulcrum, Armed Forces Institute of Regenerative Medicine, Central nervous system, Amyotrophic lateral sclerosis, Drug discovery, Neuropathology, Pontifical Xavierian University, Biogen, MS, Genomics, University, Microbiology, Neurology, ALS, Drug development, Verge, Medicine, Facioscapulohumeral muscular dystrophy, SVP, AI, FSHD, Artificial intelligence, Thought, Losmapimod, Multiple sclerosis, UTHSCSA, Georgetown University, Pharmaceutical industry, PIKFYVE, Pathology

Verge Genomics, a clinical-stage, tech-enabled biotechnology company pioneering the use of artificial intelligence (AI) and human data to transform drug discovery, announced today that it appointed Diego Cadavid, M.D., as its first Chief Medical Officer.

Key Points: 
  • Verge Genomics, a clinical-stage, tech-enabled biotechnology company pioneering the use of artificial intelligence (AI) and human data to transform drug discovery, announced today that it appointed Diego Cadavid, M.D., as its first Chief Medical Officer.
  • Before joining Verge, Dr. Cadavid served as Chief Medical Officer of X4 Pharmaceuticals where he led the clinical development of mavorixafor and recently delivered positive phase 3 data.
  • His work included the rapid advance of losmapimod from target identification to proof of concept in Facioscapulohumeral Muscular Dystrophy (FSHD).
  • What stands out to me most, though, is his knack using disruptive innovation to enable disciplined execution, said Alice Zhang, CEO and co-founder of Verge Genomics.

SARM1 Inhibitors Market by Target Indications, Type of Molecules, Drug Developers, Drug Candidates and Key Geographies : Industry Trends and Global Forecasts, 2022-2040

Retrieved on: 
Monday, December 12, 2022
Molecule, United Nations, Therapy, NIH, Peripheral neuropathy, Neurological disorder, COVID-19 drug development, Amyotrophic lateral sclerosis, Patient, Multiple sclerosis, Glaucoma, Research, Neurodegeneration, Death, Element, CPC, Alzheimer's disease, Geography, Investment, Parkinson's disease, Sterile alpha motif, Vance DeGeneres, Growth, UN, First Nations in Ontario, SARM1, Patent, Organization, Pharmaceutical industry, Fine chemical, Medical device

View original content:https://www.prnewswire.com/news-releases/sarm1-inhibitors-market-by-targ...

Key Points: 
  • In fact, the annual expenditure associated with neurological disorder care in 2020 was more than USD 655 billion, in the US alone.
  • Additionally, several patents related to SARM1 targeting therapies have been recently filed / granted, demonstrating the continued innovation in this domain.
  • Information on recent developments (partnerships and collaborations, and funding and investments) reported by several players engaged in the SARM1 targeting therapeutics domain.
  • This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments.

BrainStorm Cell Therapeutics Submits Type A Meeting Request to U.S. Food and Drug Administration

Retrieved on: 
Monday, December 12, 2022
Therapy, Chemistry, Neurodegeneration, CIRM, California Institute for Regenerative Medicine, Food, Muscle & Nerve, Merit Cudkowicz, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Amyotrophic lateral sclerosis, BLA, EMA, Orphan drug, Microsoft, Type, MS, FDA, CMC, European Medicines Agency, Lineage Cell Therapeutics, COVID-19, Cell, Annual report, Brainstorm, Safety, Inflammation, Regenerative medicine, Statistics, NTFS, Walking, Pharmaceutical industry, ALS

NEW YORK, Dec. 12, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the company has submitted a Type A Meeting Request to the U.S. Food and Drug Administration (FDA) to discuss the contents of a refusal to file letter previously issued by the FDA regarding the company's New Biologics License Application (BLA) for NurOwn® for the treatment of ALS. The Type A Meeting is expected to occur within 30 days of the FDA's receipt of the meeting request.

Key Points: 
  • As part of the Type A Meeting, BrainStorm intends to discuss a path to an FDA Advisory Committee Meeting.
  • "Participating in a Type A meeting will be an important next step towards enabling NurOwn's advancement through the regulatory process," said Chaim Lebovits, Chief Executive Officer of BrainStorm.
  • BrainStorm previously completed a Phase 3 trial in approximately 200 participants with ALS ( Cudkowicz et al., 2022 Muscle and Nerve ).
  • BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases.

ANEW MEDICAL, INC. Acquires World Wide License to Treat Neurodegenerative Diseases Using a Longevity Protein and Gene Therapy Programs.

Retrieved on: 
Wednesday, December 7, 2022
Therapy, Neurodegeneration, AAV, Waste, OTC, Chromosome, Alzheimer's disease, Amyotrophic lateral sclerosis, UAB, Protein, Metabolism, Patient, DNA, Cancer, Heart failure, Mammal, Research, Longevity, Disease, Degenerative disease, ALS, Drug development, Cell nucleus, COVID-19, Cell, Human, Ageing, LEAS, Statement, Clotho, Parkinson's disease, RNA, Chronic kidney disease, Pharmaceutical industry, Vaccine

The Klotho gene was first identified in 1997 in humans and mammals and works as a humoral factor or hormone that may regulate aging and age-related protein function and senescence (cell aging).

Key Points: 
  • The Klotho gene was first identified in 1997 in humans and mammals and works as a humoral factor or hormone that may regulate aging and age-related protein function and senescence (cell aging).
  • Our Klotho gene therapy is a unique approach to treating ALS.
  • The therapeutic results generated in experimental animal models of ALS offers great promise for patients afflicted with the disease.
  • Other neurodegenerative diseases will utilize a tissue-specific promoter, a secreted-Klotho gene variant called s-KL, and adeno-associated virus (AAV) or lipid particles to deliver the gene inside a patient's cells.

Therapeutic Solutions International Announces Improvements in Autism, Amyotrophic Lateral Sclerosis and Schizophrenia Cases Treated by Veltmeyer Institute for Advanced Therapeutics

Retrieved on: 
Monday, December 5, 2022
Research, Neurology, Hospitals, Stem Cells, Biotechnology, Other Health, Health, Other Science, Science, Henry Veltmeyer, Therapy, Neurodegeneration, Autism, Amyotrophic lateral sclerosis, TSOI, Amyotrophy, Life, Plague, Patient, FDA, ALS, Survival, Cell, Social responsibility, Schizophrenia, Pharmaceutical industry

Therapeutic Solutions International (TSOI) announced today preliminary results of a collaboration with the Veltmeyer Institute for Advanced Therapeutics aimed at providing patients with protocols, products and cells, developed by the Company.

Key Points: 
  • Therapeutic Solutions International (TSOI) announced today preliminary results of a collaboration with the Veltmeyer Institute for Advanced Therapeutics aimed at providing patients with protocols, products and cells, developed by the Company.
  • As part of the collaboration, the Veltmeyer Institute provided an update on the first three patients treated.
  • In patients with neurodegenerative diseases such as ALS (Amyotrophic lateral sclerosis), there is a correlation between survival and the number of T-regulatory cells that can actually produce nerve protective growth factors.
  • Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases.

BrainTale Has Presented the Interest If Its Digital Biomarkers Platform in Differential Diagnosis During the 15th Edition of Clinical Trials on Alzheimer’s Disease Conference

Retrieved on: 
Monday, December 5, 2022
Medical Devices, Health, Neurology, Other Health, Clinical Trials, Biotechnology, Hospital, Neurological disorder, Degenerative disease, Physician, Neurodegeneration, Clinical trial, Disease, Amyotrophic lateral sclerosis, Diagnosis, Diffusion, Dementia, Biomarker, Patient, ISO, Research, CSO, White matter, HIV disease progression rates, Neurology, Incidence, MDR, European Medical Writers Association, Axon, Ageing, Adaptive clinical trial, Brain, Myelin, Risk, Medical imaging, Pharmaceutical industry, Medical device, Alzheimer's disease

Alzheimers disease affects about 10 million people per year worldwide and its incidence rate tends to increase year after year.

Key Points: 
  • Alzheimers disease affects about 10 million people per year worldwide and its incidence rate tends to increase year after year.
  • Results show that BrainTale biomarkers are relevant biomarkers of disease severity, and that the platform has the potential for a differentiated diagnosis perspective.
  • Our data suggest a very exciting complementary approach to existing initiatives to better diagnose, and ultimately better treat Alzheimers disease patients.
  • With non-invasive, sensitive and reliable measurements of white matter microstructure alterations, BrainTale offers a digital biomarkers platform to support clinical decision-making.

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, December 2, 2022
History, Heart failure, Cytokinetics, Mechanics, Pharmacology, Amyotrophic lateral sclerosis, Employment, Muscle weakness, Research, Amend, Cyprus Securities and Exchange Commission, HCM, Patient, ALS, SAN, Pharmaceutical industry

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised.

Key Points: 
  • Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised.
  • Cytokinetics continues its over 20-year history of pioneering innovation in muscle biology and related pharmacology focused to diseases of muscle dysfunction and conditions of muscle weakness.
  • Examples of such statements include, but are not limited to, statements relating toCytokinetics'and its partners' research and development activities of Cytokinetics product candidates.
  • CYTOKINETICS and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

Cytokinetics Announces Presentation at the Virtual 33rd International Symposium on ALS/MND

Retrieved on: 
Thursday, December 1, 2022
SAN, Safe harbor, History, Pharmacology, Investigational New Drug, Act, Patient, User experience, Heart failure, International Symposium on Graph Drawing, Patent, Security (finance), Muscle weakness, Sale, Research, Intellectual property, Cytokinetics, Mechanics, Survival, Amyotrophic lateral sclerosis, FDA, HCM, Pharmaceutical industry, ALS

Cytokinetics is readying for the potential commercialization of omecamtiv mecarbil, its cardiac muscle activator, following positive results from GALACTIC-HF, a large, international Phase 3 clinical trial in patients with heart failure.

Key Points: 
  • Cytokinetics is readying for the potential commercialization of omecamtiv mecarbil, its cardiac muscle activator, following positive results from GALACTIC-HF, a large, international Phase 3 clinical trial in patients with heart failure.
  • Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act's Safe Harbor for forward-looking statements.
  • For further information regarding these and other risks related to Cytokinetics business, investors should consult Cytokinetics filings with the Securities and Exchange Commission.
  • CYTOKINETICS and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.